Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

VERA

Vera Therapeutics Inc

Feb 11 • 04:00PM ET

42.96

-1.09 -2.47 %

Healthcare • Biotechnology • USA • NASD

Peers: ARVN INCY ITCI ALXO BCRX RIGL LGND KURA CRVS AVIR

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-3.99	Insider Own	19.05%	Shs Outstand	63.89M	Perf Week	0.51%
Market Cap	3.01B	Forward P/E	-	EPS next Y	-4.66	Insider Trans	-0.32%	Shs Float	56.72M	Perf Month	-7.53%
Enterprise Value	2.59B	PEG	-	EPS next Q	-1.28	Inst Own	85.23%	Short Float	14.27%	Perf Quarter	54.81%
Income	-251.94M	P/S	-	EPS this Y	-64.79%	Inst Trans	-1.77%	Short Ratio	5.84	Perf Half Y	103.22%
Sales	0.00M	P/B	6.88	EPS next Y	-2.92%	ROA	-56.87%	Short Interest	8.09M	Perf YTD	-15.17%
Book/sh	6.24	P/C	6.05	EPS next 5Y	2.47%	ROE	-73.25%	52W High	56.05 -23.35%	Perf Year	26.20%
Cash/sh	7.10	P/FCF	-	EPS past 3/5Y	-21.52% 4.49%	ROIC	-52.97%	52W Low	18.53 131.84%	Perf 3Y	475.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.34% 5.40%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-53.44%	Oper. Margin	-	ATR (14)	2.42	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.09	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.85	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	12.09	EPS Q/Q	-48.06%	SMA20	-4.89%	Beta	1.16	Target Price	75.15
Payout	-	Debt/Eq	0.19	Sales Q/Q	-	SMA50	-7.85%	Rel Volume	0.78	Prev Close	44.05
Employees	112	LT Debt/Eq	0.19	Earnings	Nov 05 BMO	SMA200	42.21%	Avg Volume	1.39M	Price	42.96
IPO	May 14, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.40% -	Trades		Volume	1,175,032	Change	-2.47%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Initiated	BofA Securities	Buy	$48
Aug-04-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-05-25	Resumed	H.C. Wainwright	Buy	$75
Feb-04-25	Initiated	Wolfe Research	Outperform	$49
Jan-28-25	Initiated	Goldman	Buy	$58
Nov-21-24	Initiated	Wells Fargo	Overweight	$70
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Show Previous Ratings

Feb-07-26 11:35AM	Vera Therapeutics, Inc. (VERA): A Bull Case Theory (Insider Monkey)
Feb-06-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.23%
Jan-30-26 12:24AM	Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential? (Insider Monkey)
Jan-28-26 07:30AM	Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer (GlobeNewswire)
Jan-23-26 11:09AM	Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns (Insider Monkey)
11:35AM	Loading…
Jan-15-26 11:35AM	Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept (Insider Monkey)
Jan-14-26 09:55AM	Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High? (Zacks)
Jan-09-26 01:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-26 07:30AM	Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-26 07:41PM	Why Vera Therapeutics Stock Zoomed Higher Today (Motley Fool)
07:30AM	Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy (GlobeNewswire)
Dec-09-25 08:57PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire)
Dec-08-25 04:01PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Dec-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.37%
Dec-02-25 07:42PM	Why Vera Therapeutics Stock Rocked the Market on Tuesday (Motley Fool) +12.88% +10.77%
01:09PM	Loading…
01:09PM	Stock Market Today: MongoDB, Boeing, and Intel Define Tuesday Trade As Market Bounces Back From Post-Thanksgiving Blues (TheStreet)
Nov-26-25 07:45PM	Why Vera Therapeutics Stock Crushed it Today (Motley Fool) +13.25%
04:05PM	Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors (GlobeNewswire)
Nov-24-25 07:25AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-18-25 02:20PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-16-25 10:14PM	H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth (Insider Monkey)
Nov-14-25 09:01AM	Yale University's Strategic Investment in Vera Therapeutics Inc: A 32.26% Portfolio Stake (GuruFocus.com)
Nov-10-25 07:29AM	Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) +14.72%
Nov-07-25 06:27PM	Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy (GlobeNewswire)
04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:51AM	Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine (GlobeNewswire)
Nov-05-25 07:29AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 08:00AM	Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET (GlobeNewswire)
Oct-20-25 11:08PM	BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating (Insider Monkey)
Oct-17-25 09:12AM	Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 (GlobeNewswire)
04:05PM	Loading…
Oct-10-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.46%
Aug-26-25 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) +5.62%
Aug-08-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 07:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:35AM	Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 07:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 08:07AM	Millions in Insider Buying Point to These 2 Stocks Heres What It Could Signal (TipRanks)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:02AM	Biotech Stock Vera Is Slumping After Monster Gain (Barrons.com) -25.89%
07:49AM	Vera Therapeutics stock sinks following competitors successful trial (Investing.com)
Jun-04-25 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-25 06:30AM	Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans (GlobeNewswire)
02:22AM	Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 06:30AM	Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy (GlobeNewswire) +67.49%
04:51AM	Vera drug scores in closely watched study in rare kidney disease (BioPharma Dive)
May-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-25 08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -13.79%
Apr-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.76%
02:51PM	Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch (Benzinga)
Apr-03-25 08:00AM	Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN (GlobeNewswire)
Mar-11-25 04:28PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:00AM	Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.91%
Feb-26-25 08:25AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.66%
Jan-14-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 07:00AM	Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor (GlobeNewswire) -6.08%
Jan-07-25 04:05PM	Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 06:29PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-18-24 08:00AM	Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer (GlobeNewswire)
Nov-11-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:55AM	Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
08:00AM	Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study (GlobeNewswire)
Nov-08-24 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 08:21PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire) -9.23% -5.42%
09:25AM	Vera Therapeutics price target raised to $64 from $56 at Guggenheim (TipRanks)
Oct-28-24 05:43PM	Vera Therapeutics Breaks Out On Promising Results For Kidney Drug (Investor's Business Daily) +15.21%
05:37PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
10:33AM	Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years (Benzinga)
10:13AM	Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug (Investor's Business Daily)
Oct-26-24 07:30PM	Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Oct-04-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-24 06:30AM	Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
06:30AM	Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases (GlobeNewswire)
Sep-26-24 03:31PM	Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-16-24 08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 (GlobeNewswire) +6.90%
Sep-12-24 08:00AM	Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN (GlobeNewswire) -5.08%
Sep-10-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-03-24 08:27AM	Adobe Stock Added to JP Morgan Focus List. Heres Why. (Barrons.com)
08:27AM	Adobe and 2 More Stocks Added to JP Morgan Focus List. Heres Why. (Barrons.com)
07:49AM	Load Up on Adobe and These 2 Stocks This September, J.P. Morgan Says (Barrons.com)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Vera Therapeutics to Participate at September Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 04:30PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 08:00AM	Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer (GlobeNewswire)
Jun-11-24 04:01PM	Vera Therapeutics Appoints Christy J. Oliger to Board of Directors (GlobeNewswire)
Jun-07-24 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 08:00AM	Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) (GlobeNewswire)
May-25-24 09:40AM	Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress (GlobeNewswire)
May-17-24 04:27PM	Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing (MT Newswires)
May-10-24 05:38AM	Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating (MT Newswires)
May-09-24 01:53PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -5.81%
08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 17 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Sale	50.08	10,000	500,767	22,500	Dec 17 04:05 PM
ENRIGHT PATRICK G	Director	Dec 11 '25	Buy	42.50	5,882	249,985	5,882	Dec 15 08:07 PM
WILLIAM TURNER	Officer	Dec 15 '25	Proposed Sale	49.80	10,000	498,000		Dec 15 04:17 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 10 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Sale	45.31	10,000	453,053	22,500	Dec 10 04:05 PM
WILLIAM TURNER	Officer	Dec 08 '25	Proposed Sale	44.90	10,000	449,000		Dec 08 04:41 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 04 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Sale	40.00	10,000	400,000	22,500	Dec 04 04:05 PM
WILLIAM TURNER	Officer	Dec 03 '25	Proposed Sale	37.25	10,000	372,500		Dec 03 04:31 PM
Carter Jason S	Chief Legal Officer	Nov 21 '25	Sale	27.82	3,864	107,498	49,136	Nov 25 04:05 PM
Carter Jason S	Officer	Nov 21 '25	Proposed Sale	27.87	3,864	107,690		Nov 24 09:22 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 13 '25	Option Exercise	3.94	10,000	39,396	57,839	Nov 13 08:57 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 11 '25	Sale	29.06	15,000	435,874	47,839	Nov 13 08:57 PM
ENRIGHT PATRICK G	Director	Jun 23 '25	Buy	20.87	209,393	4,369,676	3,569,522	Jun 25 08:07 PM
ENRIGHT PATRICK G	Director	Jun 24 '25	Buy	22.35	40,607	907,635	3,596,593	Jun 25 08:07 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 21 '25	Sale	27.89	10,613	296,032	213,740	Feb 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 26 '25	Sale	27.65	9,075	250,882	204,665	Feb 27 04:05 PM
MARSHALL FORDYCE	Director	Feb 26 '25	Proposed Sale	27.10	9,075	245,932		Feb 26 04:21 PM

Open in Screener

SGMT

Sagimet Biosciences Inc

Feb 11 • 04:00PM ET

5.25

-0.39 -6.91 %

Healthcare • Biotechnology • USA • NASD

SGMT Sagimet Biosciences Inc daily Stock Chart

Peers: VRTX AMGN REGN GILD BIIB ILMN EXEL INCY NBIX BMRN

| Held by: VTI VXF IBB IWC AVSC DFAS DCOR DFSU DFAU IBBQ

Index	-	P/E	-	EPS (ttm)	-1.79	Insider Own	19.07%	Shs Outstand	31.00M	Perf Week	-13.65%
Market Cap	162.76M	Forward P/E	-	EPS next Y	-1.92	Insider Trans	-0.63%	Shs Float	26.32M	Perf Month	-15.87%
Enterprise Value	46.19M	PEG	-	EPS next Q	-0.43	Inst Own	33.04%	Short Float	12.94%	Perf Quarter	-36.97%
Income	-57.67M	P/S	-	EPS this Y	-14.92%	Inst Trans	-1.91%	Short Ratio	5.17	Perf Half Y	-45.03%
Sales	0.00M	P/B	1.43	EPS next Y	-15.20%	ROA	-38.04%	Short Interest	3.41M	Perf YTD	-11.32%
Book/sh	3.67	P/C	1.39	EPS next 5Y	-12.65%	ROE	-39.78%	52W High	11.41 -53.99%	Perf Year	11.23%
Cash/sh	3.76	P/FCF	-	EPS past 3/5Y	-8.32% -16.85%	ROIC	-48.36%	52W Low	1.73 203.47%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.64% 7.79%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-38.23%	Oper. Margin	-	ATR (14)	0.47	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.04	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	39.78	Recom	1.18
Dividend Gr. 3/5Y	- -	Current Ratio	13.04	EPS Q/Q	12.58%	SMA20	-11.84%	Beta	3.46	Target Price	26.90
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-13.02%	Rel Volume	1.07	Prev Close	5.64
Employees	14	LT Debt/Eq	0.00	Earnings	Nov 13 BMO	SMA200	-22.99%	Avg Volume	659.03K	Price	5.25
IPO	Jul 14, 2023	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3.63% -	Trades		Volume	702,982	Change	-6.91%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-03-26	Initiated	Guggenheim	Buy	$27
Jan-28-26	Initiated	Barclays	Equal Weight	$8
Aug-11-25	Initiated	Wedbush	Outperform	$28
Aug-07-25	Resumed	H.C. Wainwright	Buy	$29
Jul-24-25	Initiated	Canaccord Genuity	Buy	$28
Dec-06-24	Initiated	Oppenheimer	Outperform	$30
Nov-12-24	Initiated	UBS	Buy	$12
Jun-28-24	Downgrade	Goldman	Buy → Neutral	$23 → $6
May-02-24	Initiated	H.C. Wainwright	Buy	$32
Mar-25-24	Initiated	Leerink Partners	Outperform	$26
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Piper Sandler	Overweight	$67
Aug-08-23	Initiated	JMP Securities	Mkt Outperform	$30
Aug-08-23	Initiated	Goldman	Buy	$33

Show Previous Ratings

Feb-05-26 07:00AM	Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences (GlobeNewswire) -10.53%
Feb-03-26 03:27PM	After Clearing Up Acne, Sagimet Stock Rises (Barrons.com) +5.30%
09:34AM	Adobe downgraded, Palantir upgraded: Wall Street's top analyst calls (The Fly)
Feb-02-26 07:00AM	Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne (GlobeNewswire) +9.88%
Jan-08-26 07:00AM	Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference (GlobeNewswire)
07:00AM	Loading…
Dec-18-25 07:00AM	Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination (GlobeNewswire)
Dec-17-25 07:00AM	Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet's Fixed Dose Combination Program (GlobeNewswire)
Dec-10-25 07:03AM	Sagimet's License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China's National Medical Products Administration (GlobeNewswire)
Dec-09-25 04:05PM	Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-25 07:00AM	Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference (GlobeNewswire) -7.39%
Nov-13-25 07:30AM	Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) -12.24%
Nov-10-25 07:00AM	Sagimet Biosciences Presents Two Denifanstat Posters at AASLD-The Liver Meeting 2025 (GlobeNewswire) +10.77%
Oct-24-25 07:00AM	Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference (GlobeNewswire) +24.69%
Oct-15-25 12:00PM	All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy (Zacks)
Oct-14-25 07:00AM	Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Oct-07-25 07:00AM	Sagimet Biosciences Announces Upcoming Presentation at AASLD-The Liver Meeting 2025 (GlobeNewswire)
Oct-01-25 07:00AM	Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination (GlobeNewswire)
Sep-24-25 07:00AM	Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week (GlobeNewswire) +8.17%
Sep-17-25 07:00AM	Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis (GlobeNewswire)
Sep-16-25 09:35AM	Here's Why Sagimet Biosciences Inc. (SGMT) is Poised for a Turnaround After Losing 15.8% in 4 Weeks (Zacks)
Sep-10-25 07:00AM	Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit (GlobeNewswire)
Aug-26-25 07:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:00PM	Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) (Zacks)
Aug-13-25 07:30AM	Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-07-25 09:56AM	Eli Lilly downgraded, Lyft upgraded: Wall Street's top analyst calls (The Fly)
Aug-05-25 07:00AM	Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire) +6.04%
Jun-11-25 12:00PM	What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now? (Zacks)
Jun-09-25 09:55AM	Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know (Zacks)
07:00AM	Sagimet Biosciences to Host Virtual KOL Event, "A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne" on June 16, 2025 (GlobeNewswire)
07:02AM	Loading…
Jun-06-25 07:02AM	Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update (BioPharma Dive) +16.32%
Jun-04-25 08:28AM	Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps (Benzinga) +12.40%
05:00AM	Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis (GlobeNewswire)
May-22-25 08:00AM	Sagimet Biosciences to Host Virtual KOL Event, "Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)" on May 29, 2025 (GlobeNewswire) +5.90%
May-08-25 06:00AM	Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-23-25 08:00AM	Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025 (GlobeNewswire) +8.82%
Mar-12-25 07:30AM	Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
Mar-11-25 08:00AM	Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne (GlobeNewswire)
Feb-25-25 08:25AM	Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In? (Insider Monkey)
Feb-22-25 05:24PM	Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now (Insider Monkey)
Feb-19-25 08:00AM	Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium (GlobeNewswire)
Jan-06-25 08:00AM	Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference (GlobeNewswire) +36.42%
Dec-15-24 06:04AM	Oppenheimer Predicts Up to ~580% Jump for These 2 Strong Buy Stocks (TipRanks)
Nov-26-24 08:00AM	Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-18-24 08:00AM	Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting 2024 (GlobeNewswire) -7.82%
Nov-14-24 08:00AM	Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -13.95%
Nov-12-24 06:30AM	Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne (PR Newswire)
Nov-07-24 07:30AM	Sagimet Biosciences to Participate in the UBS Global Healthcare Conference (GlobeNewswire)
Oct-29-24 07:00AM	Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024 (GlobeNewswire)
Oct-16-24 07:00AM	Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting 2024 (GlobeNewswire) +6.43%
Oct-11-24 07:00AM	Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
Oct-01-24 07:00AM	Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH (GlobeNewswire) +12.64%
12:05AM	Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-12-24 07:30AM	Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit (GlobeNewswire) -9.57%
Sep-04-24 08:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 08:00AM	Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.14%
Aug-01-24 08:00AM	Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jun-10-24 08:00AM	Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat (GlobeNewswire)
Jun-06-24 05:00AM	Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024 (GlobeNewswire)
May-16-24 08:00AM	Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024 (GlobeNewswire)
May-15-24 12:53PM	SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024 (InvestorPlace) +5.48%
08:00AM	Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-07-24 08:00AM	Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024 (GlobeNewswire)
May-06-24 08:00AM	Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer (GlobeNewswire)
Apr-22-24 08:00AM	Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024 (GlobeNewswire)
Mar-27-24 04:01PM	Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat (GlobeNewswire) +9.56% -5.41%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) +15.74%
06:15AM	Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Feb-29-24 08:00AM	Sagimet Biosciences to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Jan-25-24 08:58PM	Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock (GlobeNewswire) -13.62% -23.89%
Jan-23-24 05:45PM	Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock (GlobeNewswire) -7.31%
Jan-22-24 11:10PM	Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH (PR Newswire) +170.09%
07:00AM	Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH (GlobeNewswire)
Dec-04-23 08:00AM	Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic (GlobeNewswire) +7.12%
Nov-28-23 08:00AM	Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit (GlobeNewswire)
Nov-22-23 08:00AM	Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +13.58%
Nov-13-23 08:00AM	Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -13.73%
Nov-10-23 08:30AM	Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023 (GlobeNewswire) -7.68%
Oct-24-23 11:00AM	Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting 2023 (GlobeNewswire)
Oct-18-23 04:05PM	Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference (GlobeNewswire) -17.06%
Sep-27-23 04:05PM	Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma (GlobeNewswire)
Aug-29-23 10:21AM	Load Up, Says Goldman Sachs About These 2 Strong Buy Stocks (TipRanks)
Aug-21-23 04:02PM	Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) -13.73%
Aug-15-23 04:04PM	Sagimet Biosciences Announces Closing of Underwriters Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering (GlobeNewswire) -7.71%
Aug-08-23 10:02AM	DraftKings upgraded, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
Jul-20-23 04:05PM	Sagimet Biosciences Announces Leadership Changes (GlobeNewswire)
Jul-13-23 09:10PM	Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kemble George	Executive Chairman	Nov 20 '25	Sale	7.69	37,688	289,979	81,005	Nov 21 06:13 PM
GEORGE KEMBLE	Director	Nov 20 '25	Proposed Sale	7.85	37,688	295,851		Nov 20 04:21 PM
Happel David	President & CEO	Jul 21 '25	Sale	9.13	65,478	598,115	689,722	Jul 23 04:16 PM
Martins Eduardo Bruno	Chief Medical Officer	Jul 21 '25	Sale	9.13	8,277	75,607	106,936	Jul 23 04:15 PM
Rozek Elizabeth	General Counsel and CCO	Jul 21 '25	Sale	9.13	10,780	98,471	183,726	Jul 23 04:14 PM

VERA

Vera Therapeutics Inc

SGMT

Sagimet Biosciences Inc

Upgrade your FINVIZ experience